首页> 外文期刊>Medical science monitor : >Efficacy of Ligustrazine Injection as Adjunctive Therapy for Angina Pectoris: A Systematic Review and Meta-Analysis
【24h】

Efficacy of Ligustrazine Injection as Adjunctive Therapy for Angina Pectoris: A Systematic Review and Meta-Analysis

机译:川gust嗪注射液作为心绞痛辅助治疗的疗效:系统评价和荟萃分析

获取原文
           

摘要

BACKGROUND In the past decades, a large number of randomized controlled trials (RCTs) on the efficacy of ligustrazine injection combined with conventional antianginal drugs for angina pectoris have been reported. However, these RCTs have not been evaluated in accordance with PRISMA systematic review standards. The aim of this study was to evaluate the efficacy of ligustrazine injection as adjunctive therapy for angina pectoris. MATERIAL AND METHODS The databases PubMed, Medline, Cochrane Library, Embase, Sino-Med, Wanfang Databases, Chinese Scientific Journal Database, Google Scholar, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, and the Chinese Science Citation Database were searched for published RCTs. Meta-analysis was performed on the primary outcome measures, including the improvements of electrocardiography (ECG) and the reductions in angina symptoms. Sensitivity and subgroup analysis based on the M score (the refined Jadad scores) were also used to evaluate the effect of quality, sample size, and publication year of the included RCTs on the overall effect of ligustrazine injection. RESULTS Eleven RCTs involving 870 patients with angina pectoris were selected in this study. Compared with conventional antianginal drugs alone, ligustrazine injection combined with antianginal drugs significantly increased the efficacy in symptom improvement (odds ratio [OR], 3.59; 95% confidence interval [CI]: 2.39 to 5.40) and in ECG improvement (OR, 3.42; 95% CI: 2.33 to 5.01). Sensitivity and subgroup analysis also confirmed that ligustrazine injection had better effect in the treatment of angina pectoris as adjunctive therapy. CONCLUSIONS The 11 eligible RCTs indicated that ligustrazine injection as adjunctive therapy was more effective than antianginal drugs alone. However, due to the low quality of included RCTs, more rigorously designed RCTs were still needed to verify the effects of ligustrazine injection as adjunctive therapy for angina pectoris.
机译:背景技术在过去的几十年中,已经报道了关于川gust嗪注射液与常规抗心绞痛药物联合治疗心绞痛疗效的大量随机对照试验(RCT)。但是,尚未根据PRISMA系统审查标准对这些RCT进行评估。这项研究的目的是评估川gust嗪注射液作为心绞痛的辅助疗法的疗效。材料和方法在PubMed,Medline,Cochrane图书馆,Embase,Sino-Med,Wanfang数据库,中文科学期刊数据库,Google Scholar,中国生物医学文献数据库,中国国家知识基础设施和中国科学引文数据库中进行搜索,以查找已发布的RCT 。对主要结局指标进行荟萃分析,包括改善心电图(ECG)和减轻心绞痛症状。还使用基于M得分(精确的Jadad得分)的敏感性和亚组分析来评估所含RCT的质量,样本量和出版年份对川gust嗪注射液总体效果的影响。结果本研究选择了涉及870例心绞痛患者的11项RCT。与单独使用传统抗心绞痛药物相比,川gust嗪注射液联合抗心绞痛药物显着提高了症状改善的功效(几率[OR]为3.59; 95%置信区间[CI]:2.39至5.40)和ECG改善(OR为3.42; 95%CI:2.33至5.01)。敏感性和亚组分析还证实了川li嗪注射液作为辅助治疗心绞痛的疗效更好。结论11项符合条件的RCT表明,川gust嗪注射液作为辅助治疗比单独使用抗心绞痛药物更有效。但是,由于所含RCT的质量较差,因此仍需要更严格设计的RCT来验证川azine嗪注射液作为心绞痛辅助治疗的效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号